BioCentury | Mar 10, 2018
Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
BioCentury | Sep 14, 2015

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
Items per page:
1 - 2 of 2